Abstract
Cholera is a severe diarrheal disease caused by Vibrio cholerae and remains as a major health risk in developing countries. The emergence and spread of multi-drug resistant V. cholerae strains during the past two decades is now a major problem in the treatment of cholera and have created the urgent need for the development of novel therapeutic agents. Targeting transcriptional factor is now a novel approach to tackle the development of multi-drug resistant strain. In the recent year virtual high throughput screening has emerged as a widely accepted powerful technology in the identification of novel and diverse lead. This study provides new insight to the search for new potent and selective inhibitors that still remains necessary to avoid the risk of possible resistance and reduce toxicity and side effects of currently available cholera drugs. The publications of high resolution X-ray structure of V. cholerae ToxT has open the way to the structure based virtual screening to identify new small molecular inhibitors which still remain necessary to avoid the risk of possible resistance and reduce toxicity and side effects of currently available cholera drugs. In this study we have performed structure based virtual screening approach using NCI diversity set-II to look for novel inhibitor of ToxT and proposed eight candidate compounds with high scoring function. Thus from complex scoring and binding ability it is elucidated that these compounds could be the promising inhibitors or could be developed as novel lead compounds for drug design against cholera.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anne, E.C., Emily, P., Deborah, T.H. 2007. Targeting virulence: a new paradigm for antimicrobial therapy. Nature Chemical Biology 3, 541–548.
Athanasios, G.P. 1998. Transcription-factormodulating agents: precision and selectivity in drug design. Molecular Medicine Today (Review) 8, 358–66.
Baell, J.B., Holloway, G.A. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 53, 2719–2740.
Barua. D. 1972. The global epidemiology of cholera in recent years. Proc R Soc Med. 65, 423–428.
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H. 2000. “The protein data bank.” Nucleic Acids Res 28, 235–242.
Blum, L.C., Reymond, J.L. 2009. 970 million drug like small molecules for virtual screening in the chemical universe database GDB-13. J Am Chem Soc 131, 8732–8733.
Brandon, M.C., Xiao H.C., Gregor, G.W., Borries, D., Harts, P.J., Karl, E.K. 2011. N-terminal Residues of the Vibrio cholerae Virulence Regulatory Protein ToxT Involved in Dimerization and Modulation by Fatty Acids. J Biol Chem 286, 28644–28655.
Butler, D. 2010. Cholera tightens grip on Haiti. Nature 468, 483–484.
Chakraborty, S., Garg, P., Ramamurthy, T., Thungapathra, M., Gautam, J.K., Kumar, C., Maiti, S., Yamasaki, S., Shimada, T., Takeda, Y., Ghosh, A., Nair G.B. 2001. Comparison of antibiogram, virulence genes, ribotypes and DNA fingerprints of Vibrio cholerae of matching serogroups isolated from hospitalized diarrhoea cases and from the environment during 1997–1998 in Calcutta, India. J Med Microbiol 50, 879–88.
Champion, G.A., Neely, M.N., Brennan, M.A., DiRita, V.J. 1997. A branch in the ToxR regulatory cascade of Vibrio cholerae revealed by characterization of toxT mutant strains. Mol Microbiol 23, 323–331.
Chatterjee, S., Asakura, M., Chowdhury, N., Neogi, S.B., Sugimoto, N., Haldar, S., Awasthi, S.P., Hinenoya, A., Aoki, S., Yamasaki, S. 2011. Capsaicin, a potential inhibitor of cholerae toxin production in Vibrio cholerae. FEMS Microbiol Lett 306, 54–60.
Das, S., Saha, R., Kaur, I.R. 2008. Trend of antibiotic resistance of Vibrio cholerae strains from East Delhi. Indian J Med Res 127, 478–82.
David, A.R, Vanessa, S. 2010. Anti-virulence strategies to combat bacteria-mediated disease. Nature Reviews Drug Discovery 9, 117–128.
DeLano, W.L. 2002. The PyMOL Molecular Graphics System. San Carlos, CA, USA: DeLano Scientific. http://www.pymol.org.
DiRita, V. J., Parsot, C., Jander, G., Mekalanos, J.J. 1991. Regulatory cascade controls virulence in Vibrio cholerae. Proc Natl Acad Sci 88, 5403–5407.
DiRita, V. J., Neely, M., Taylor, R. K., Bruss, P. M. 1996. Differential expression of the ToxR regulon in classical and E1 Tor biotypes of Vibrio cholerae is due to biotype-specific control over toxT expression. Proc Natl Acad Sci 93, 7991–7995.
Duan, Y., Wu, C., Chowdhury S., Lee, M.C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., Caldwell, J., Wang, J., Kollman, P. 2003. A pointcharge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24, 1999–2012.
Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., Liang, J. 2006. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 34, W116–W118.
Ekins, S., Boulanger, B., Swaan, P.W., Hupsey, M.A. 2002. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. Jol Computer aided mol dsgn 16, 381–401.
Faruque, A.S., Alam, K., Malek, M.A., Khan, M.G.., Ahmed, S., Saha, D., Khan, W.A., Nair, G. B., Salam, M.A., Luby, S.P. & Sack, D.A. 2007. Emergence of Multidrug-resistant Strain of Vibrio cholerae spp O1 in Bangladesh and Reversal of Their Susceptibility to Tetracycline After Two Years. J Health Popul Nutr 25, 241–243.
Fersht, A.R., Shi, J.P., Knill-Jones, J., Lowe, D.M., Wilkinson, A.J., Blow, D.M., Brick, P., Carter, P., Waye, M.M., Winter, G. 1985. Hydrogen bonding and biological specificity analyzed by protein engineering. Nature 314, 235–238.
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T.A., Klicic, J. J., Mainz, D. T., Repasky, M.P., Knoll, E.H., Shaw, D.E., Shelley, M., Perry, J.K., Francis, P., Shenkin, P. S. 2004. Glide: a new approach for rapid, accurate docking and scoring method and assessment of docking accuracy. J Med Chem 47, 1739–49.
Garber K. 2006. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech. Science 312, 827.
Heberlé, G., de Azevedo, W.F. 2011. Bio-Inspired Algorithms Applied to Molecular Docking Simulations. Current Medicinal Chemistry 18, 1339–1352.
Herrington, D.A., Hall, R.H., Losonsky, G., Mekalanos, J.J., Taylor, R.K., Levine, M.M. 1988. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168, 1487–1492.
Higgins, D.E. and DiRita, V.J. 1994. Transcriptional control of toxT, a regulatory gene in the ToxR regulon of Vibrio cholerae. Mol Microbiol 14, 17–29.
Humphrey, W., Dalke, A. and Schulten, K. 1996. “VMD — Visual Molecular Dynamics”, J Molec Graphics 14, 33–38.
Hung, D.T., Shakhnovich, E.A., Pierson, E., Mekalanos, J.J. 2005. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670–674.
Kapetanovic, I.M. 2008. Computer-aided Drug Discovery and Development (CADDD): in silico-chemicobiological approach. Chem Biol Interact 171, 165–176.
Karamouzis, M.V., Gorgoulis, V.G., Papavassiliou, A.G. 2000. Transcription Factors and Neoplasia: Vistas in Novel Drug Design. Clin Cancer Res 8, 949–61.
Katie, J. Simmons., Chopra, I., Fishwick, C.W.G. 2010. Structure-based discovery of antibacterial drugs. Nature Reviews Microbiology 8, 501–510.
Kitaoka, M., Miyata, S.T., Unterweger, D., Pukatzki, S. 2011. Antibiotic resistance mechanisms of Vibrio cholerae. J Med Microbiol 60, 397–407.
Konstantinopoulos, P.A., Papavassiliou, A.G. 2011. Seeing the Future of Cancer-Associated Transcription Factor Drug Targets. JAM 305, 2349–2350.
Lagorce, D., Maupetit, J., Baell, J., Sperandio, O., Tuff’ery P., Miteva, M.A., Galons, H., Villoutreix, B.O. 2011. The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics. 27, 2018–2020.
Lipinski, C.A., Lombardo F., Dominy, B.W., Feeney, P.J. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3–26.
Lowden, M.J., Skorpupski, K., Pellegrini, M., Chiorazzo, M.G., Taylor, R.K., Kull, F.J. 2010. Structure of Vibrio cholerae ToxT reveals a mechanism for Fatty acid regulation of virulence genes. Proc Natl Acad Sci 107, 2860–2865.
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., Olson, A. J. 2009. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 16, 2785–2791.
Natsumi, B & Akaho, E. 2011. VSDK: Virtual screening of small molecules using Autodock Vina on Windows platform. Bioinformation 6, 387–388.
Perola, E., Walters, W.P, Charifson, P.S. 2004. A detailed comparison of current docking and scoring methods on system of pharmaceutical relevance. Proteins 56, 235–249.
Petsko, G. A. 2010. When failure should be the option. BMC Biology 8, 61.
Pierce N. F., Banwell, J. G., Mitra, R. C., Caranasos, G. J., Keimowitz, R. I.., Thomas, J., Mondal, A. 1968. Controlled comparison of tetracycline and furazolidone in Cholera. BMJ 3, 277–280.
Pollitzer, R. Cholera. 1959. World Health Organization, Geneva, Switzerland 58, 1001–1019.
Rappe, A.K., Casewit, C.J., Colwell, K.S., Goddard, W. A. III., Skiff, W. M. 1992. UFF, a Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations, J A Chem Soc 114, 10024–10035.
Romano T.K. 2007. Structure-Based Drug Design: Docking and Scoring. Current Protein and Peptide Science 8, 312–328.
Ruvinsky, A.M., Kozintsev, A.V. 2006. Novel statistical-thermodynamic methods to predict proteinligand binding positions using probability distribution functions. PROTEINS: Structure function and bioinformatics 62, 202–208.
Skorupski, K., Taylor R. K. 1997. Control of the ToxR virulence regulon in Vibrio cholerae by enviromental stimuli. Mol Microbiol. 25, 1003–1009.
Souse, S.F., Fernandes, P.A., Ramos, M.J. 2006. Protein-ligand docking: current status and future challenges. Protein 65, 15–26.
Szileigyl, G. 1984. Arzneimittel Forshung -Drug Research 35, 1260.
Walters, W.P., Stahl, M.T. and Murcko, M.A. 1998. Virtual screening — an overview. Drug Discov Today. 3: 160–178.
Waszkowycz, B., Perkins, T. D. J., Sykes, R.A. J. 2001. Large-scale virtual screening for discovering leads in the post-genomic era. IBM systems journal-Deep computing for the life sciences 40, 360–376.
Xu, D., Lin, S.L., Nussinov, R. 1997a. Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. J Mol Biol 265, 68–84.
Xu, D., Tsai, C.J., Nussinov, R. 1997b. Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Engineering 10, 999–1012.
Author information
Authors and Affiliations
Corresponding author
Additional information
Equal contribution to the work.
Rights and permissions
About this article
Cite this article
Mondal, S.I., Khadka, B., Akter, A. et al. Computer based screening for novel inhibitors against Vibrio cholerae using NCI diversity set-II: An alternative approach by targeting transcriptional activator ToxT. Interdiscip Sci Comput Life Sci 6, 108–117 (2014). https://doi.org/10.1007/s12539-012-0046-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12539-012-0046-8